Medications, specifically exogenous insulin, statins, and in the future, glucagon-like peptide 1 receptor agonists and sodium–glucose cotransporter 2 inhibitors, may modify the relationship between T2DM, glycemic control, and prostate cancer (41). This evidence concerns the gene GLP1R and prostate cancer.